tiprankstipranks
Advertisement
Advertisement
Nasus Pharma advances NS002 to pivotal study following Phase 2 results
PremiumThe FlyNasus Pharma advances NS002 to pivotal study following Phase 2 results
5M ago
Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)
Premium
TipRanks Newswire
Nasus Pharma’s NS002 Demonstrates Consistent Early Advantage in Epinephrine Delivery (NYSE: NSRX)
5M ago
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
Premium
TipRanks Newswire
Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
5M ago
Nasus Pharma files to sell 5.39M ordinary shares for holders
PremiumThe FlyNasus Pharma files to sell 5.39M ordinary shares for holders
6M ago
Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)
Premium
TipRanks Newswire
Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)
6M ago
Nasus Pharma Files Updated Corporate Presentation With SEC
Premium
Company Announcements
Nasus Pharma Files Updated Corporate Presentation With SEC
6M ago
Nasus Pharma Ltd trading halted, volatility trading pause
PremiumThe FlyNasus Pharma Ltd trading halted, volatility trading pause
6M ago
Nasus Pharma Raises $15 Million in Premium-Priced Private Placement to Fund NS002 Pivotal Program
Premium
Company Announcements
Nasus Pharma Raises $15 Million in Premium-Priced Private Placement to Fund NS002 Pivotal Program
6M ago
Nasus Pharma Prices $15 Million Premium Private Placement to Fund NS002 Pivotal Push
Premium
Company Announcements
Nasus Pharma Prices $15 Million Premium Private Placement to Fund NS002 Pivotal Push
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100